MabDesign joins EuropaBio: innovation linked to the industrial field of biotherapy
Brussels, 14 December 2021 – EuropaBio is pleased to announce that MabDesign has joined as an associate member. MabDesign, the French biotherapy industrial association, aims to support, federate and increase the visibility of the biopharmaceutical industry since the R&D phases until bioproduction and clinical phases, foster exchanges, promote the development and competitiveness of companies, and stimulate innovation by encouraging the emergence of start-ups from academic research.
In order to carry out its development strategy and to adapt to changes in the industrial ecosystem, MabDesign’s governance is composed of DBV Technologies, Lyonbiopole, Pierre Fabre, Sanofi, ABL Europe, bioMérieux, Institut Pasteur, Thermo Fisher Scientific and TreeFrog Therapeutics as well as three Qualified Persons with Nicola Beltramineli (Lysogene), Hervé Broly (Merck) and Stéphane Legastelois (33 California). The diversity of MabDesign’s board of directors allows to closely follow the needs and challenges of the industrial biotherapy sector.
MabDesign currently counts with more than 215 member companies.
EuropaBio Director-General Dr. Claire Skentelbery commented “MabDesign represents the future of European advanced medicines, with an extensive network of companies from start-ups through to multi-nationals. The innovation base and strength of such a community helps EuropaBio to support Europe’s development as a world leader in advanced therapeutics for patients”.
Nicolas Groux, CEO at MabDesign, added: “We are glad to be part of EuropaBio and we believe that by joining the association we can voice up the expertise that our members have and it will contribute to promote exchanges and collaborations at the European level”.